Part of F-star Therapeutics, Inc., Sperovie Biosciences, Inc. is an American company. The firm engages in drug discovery and development services.

F-Star Therapeutics is a biopharmaceutical company dedicated to developing novel bispecific antibody products that provide a significant improvement over the current standard of care. Given its strong patent position, it is the only biopharmaceutical company with the ability to create and develop Fcab:tm: antibody fragments, and bispecific antibodies, by modifying the constant region of an antibody. In particular, F-star’s Modular Antibody Technology:tm: enables rapid discovery and development of bispecific antibodies by introducing additional binding sites to the constant region of an antibody and offers unprecedented ease in the development and manufacturing of bispecific monoclonal antibodies. Using the Modular Antibody Technology, F-star generates bispecific antibodies (mAb2:tm:) that possess the favourable characteristics of traditional monoclonal antibodies, without the production challenges often associated with other antibody formats. F-star is now applying its proprietary technology to the development of a pipeline of product candidates. Since its founding in 2006 the company has secured funding and support from leading VC investors: Aescap Venture, Atlas Venture, Novo Ventures and TVM Capital; as well as from renowned strategic corporate investors: Merck Serono Ventures, MP Healthcare Venture Management and SR One. In 2013, F-star established an asset-centric vehicle structure through the formation of F-star Alpha Ltd., which included out-licensing of FS102 from F-star to F-star Alpha Ltd. In October 2014 Bristol-Myers Squibb obtained an exclusive option to buy F-star Alpha. In addition the company has alliances with Boehringer Ingelheim and Merck Serono, each covering multiple targets. In 2011, F-star was selected by FierceBiotech as one of the Fierce 15 winners. F-star currently employs over 35 people at its research site in Cambridge, UK.

The Institute Pasteur is a private, non-profit foundation. Its mission is to help prevent and treat diseases, mainly those of infectious origin, through research, teaching, and public health initiatives.The Institut Pasteur is a research center of international renown ideally located in the very heart of Paris. Each year the institute hosts a multitude of scientific and medical conferences and meetings as well as events on a variety of themes.

Shanghai Feisheng Biotechnology Co., Ltd., established on 2018-07-25, The scope of business includes engaging in biotechnology,Technology development in the field of medical science and technology,technical consulting,Technical Services,technology transfer,Office Supplies,communication equipment,computer,Software and Auxiliary Equipment,Wujinjiaodian,Daily necessities,building decoration materials,Instrumentation,electronic product,Wholesale of Class I Medical Devices,retail,Business Consulting,Own Equipment Rental. [Items subject to approval by law,Business activities can only be carried out after approval by relevant departments]

Institut National de la Sant? et de la Recherche M?dicale provides medical services. The firm specializes in biomedical research and public health research. The company is headquartered in Paris, Cedex, France.

Peking Union Medical College Hospital, also known as Beijing Xiehe Hospital (Chinese: 北京协和医院), is a renowned general hospital in Beijing, China. It was founded in 1921 by Rockefeller Foundation and is affiliated to both Peking Union Medical College (PUMC) and Chinese Academy of Medical Sciences (CAMS). During the Cultural Revolution, it was renamed the "Anti-imperialist Hospital".

Suzhou Fangke Biotechnology Co., Ltd., established on 2018-05-14, Business scope includes licensed projects:Production of Class II Medical Devices;Production of Class III Medical Devices;Inspection and testing service;Class III medical device business;Technology Import and Export(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,Specific business projects are subject to approval results) General project:Medical Research and Experimental Development;Production of Class I Medical Devices;Sales of Class I Medical Devices;Sales of Class II Medical Devices;software development;Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Development of Human Gene Diagnosis and Therapy Technology;Instrument sales;Information Technology Consulting Services(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)

Century Yibu (Hangzhou) Medical Diagnostic Technology Co., Ltd., established on 2018-07-02, Business scope includes production:First,two,Class III medical devices and in vitro diagnostic reagents,Detection Reagent(Not for medical or diagnostic purposes),Experimental Reagents(Not for medical or diagnostic purposes),Non-medical laboratory analysis instruments,computer peripherals;Sales:Detection Reagent(Not for medical or diagnostic purposes),Chemical Products(In addition to hazardous chemicals and toxic chemicals),Self-produced products and provide related technologies,Consulting and after-sales service;Research,to develop:Medical Laboratory Diagnostic Supplies,Diagnostic reagents and related instruments,Equipment and its software;technology development,Technical Services,technical consulting,Achievement transfer:Biotechnology,computer information technology,computer software;Serve:Transfer of medical laboratory diagnostic technology;Import of self-produced raw materials and accessories for production,Export of self-produced products.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Meiji Co., Ltd. produces and sells milk, dairy, confectioneries, and food. Its products include cheese, ice cream, chocolate, infant formula, whey protein, beauty supplements, and yogurt. The company was founded on December 21, 1917 and is headquartered in Tokyo, Japan.

Oncovir is a pharmaceutical company dedicated to the development of nucleic-acid-based clinical therapies for cancer, infectious, immune, and degenerative disorders. It promotes Hiltonol (poly-ICLC) as an experimental viral mimic and broad activator of innate immunity. While initially developed as an interferon inducer, Hiltonol has much broader biological effects in humans, including specific antiviral, immune activating, vaccine adjuvant, and antitumor actions.

Zhuhai Lihe Medical Diagnostic Products Co., Ltd., established on 2014-05-21, Business scope includes licensed projects:Production of Class II Medical Devices;Production of Class III Medical Devices;Class III medical device business;Class III Medical Device Leasing.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,Specific business projects are approved by relevant departments,documents or permits shall prevail)General project:Sales of Class II Medical Devices;Class II Medical Device Leasing;Production of Class I Medical Devices;Sales of Class I Medical Devices;Class I Medical Device Leasing;Manufacturing of special equipment(Manufacture of licensed professional equipment not included);Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Import and export;Office Supplies Sales;Sales of office equipment consumables;Office Equipment Sales.(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)

Manufactures vaccines for diseases like hepatitis, influenza, rubella and typhoid fever

Zhuhai Livzon Diagnostics, Inc. engages in the development, production, and marketing of in-vitro diagnostic (IVD) products. Its products include diagnostic kit for Immunoglobulin M (IgM) / Immunoglobulin G (IgG) antibody to coronavirus (SARS-CoV-2), autoimmunity multiple detection platform, chemiluminescence detection platform, nucleic acid molecule detection platform, and X-ray blood irradiator. The company was founded on January 26, 1989 and is headquartered in Zhuhai, China.

Skyhawk Therapeutics is a provvider of small molecule therapeutics designed to offer therapies that correct RNA expression.The company's therapeutics use proprietary technology that helps the rational design of small molecules that target specific binding pocket regions on RNA, using both sequence and structural specificity, at particular moments in the RNA splicing process, enabling physicians to target diseases driven by a type of RNA mis-splicing called exon skipping.